Ledger Gazette |
FDA approves Mepolizumab for maintenance treatment of severe asthma
Ledger Gazette The US Food and Drug Administration has cleared use of Nucala (mepolizumab) in patients with severe asthma aged 12 years and older whose condition is driven by eosinophilic inflammation, offering patients access to the first and only approved biologic … Nucala approved to treat severe asthma |
View full post on asthma – Google News